OSE Immunotherapeutics is trading higher on the Paris Bourse on Thursday, following the presentation of preclinical data on its therapeutic mRNA platform for the treatment of autoimmune and inflammatory diseases.

Results show that its therapeutic mRNA using a lipid nanoparticle vector enables selective delivery and local expression of the immunosuppressive cytokine IL-35 in the liver.

Another finding is that IL-35 therapeutic mRNA can suppress chronic and acute hepatic autoimmune inflammation in various preclinical mouse models by inhibiting B and T cell activation.

Finally, specific inhibition of autoantibodies was observed after treatment with IL-35 mRNA therapeutics in an inflammatory model of chronic hepatitis.

From OSE's point of view, these results open up treatment prospects, particularly in autoimmune hepatitis, a serious inflammatory and immune disorder of the liver with a significant unmet medical need.

These data were presented as a poster at the FOCIS (Federation of Clinical Immunology Societies) annual meeting currently taking place in San Francisco.

Copyright (c) 2024 CercleFinance.com. All rights reserved.